RE:2ND QUARTER 2121 2/2Really not a big fan of seeing share based compensation at over 2x revenues. Friggin ugly.
Rev growth is nice, but expected. A lot of delays in trials and studies, which while expected, isnt so nice.
Really think this Q is defined by what happens with the big negotiation down south